-
YM BioSciences partner Oncoscience AG reports update of pediatric brain cancer data
Oncoscience | September 30th, 2005
Nimotuzumab (Theraloc;TheraCIM h-R3) Phase II results awarded best poster prize at the 37th congress of the Internationa...
-
YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma
Oncoscience | March 1st, 2005
TheraCIM h-R3 (nimotuzumab) Phase II Results Presented at European High Grade Glioma Conference MISSISSAUGA, ON, Feb. 2...
-
YM Biosciences and Oncoscience AG achieve clinical milestone
Oncoscience | January 10th, 2005
Results Permit Pediatric Brain Cancer Trial to be Converted into Pivotal Randomized First-Line Therapy Trial MISSISSAUG...
